India Pharma Outlook Team | Tuesday, 07 July 2026
Indian healthcare sector transforms as pharmaceuticals step beyond traditional roles to make advanced treatments more accessible and affordable.
High medical costs often become a barrier for patients, especially for critical illnesses like cancer. Therefore, collaborations between healthcare innovators and financial service providers emerge as a powerful solution to bridge the affordability gap.
Cancer treatment, particularly advanced therapies, can cost between lakhs to over Rs 30 lakhs. That often becomes an immense financial strain on families. Many patients delay or even abandon treatment due to the inability to arrange large upfront payments.
Recognizing this challenge, companies are now introducing patient-centric financial solutions that allow individuals to focus on recovery rather than immediate financial burdens.
The partnership between healthcare organisations and financial institutions is increasing. This is due to the increasing trend of making life-saving medication accessible to people immediately.
This indicates the need for inclusive healthcare, which includes affordability as one of the basic principles of innovations in the medical field. One of the ways of how financial service providers contribute to inclusive healthcare is through providing special medical loans.
Which is specifically designated for urgent treatments. This type of service helps to get money quickly with no documentation and flexible repayment schemes. It is for people who have complicated medical histories and need to receive treatment immediately.
For patients with complicated medical histories, people who are under multiple therapies or people with the late stages of the disease, getting money on time becomes vital because it saves lives. Financial assistance schemes help patients avoid stressful situations and continue their treatment without any interruptions.
Also Read: Pharmaceutical 4.0: Redefines Compliance, Automation & AI
Immuneel Therapeutics has partnered with Arogya Finance to launch a zero-cost EMI programme of up to Rs 25 lakh for eligible cancer patients. This initiative aims in making advanced cancer treatments, including cutting-edge cell and gene therapies, which should be more financially accessible.
The programme is part of Immuneel’s patient access initiative, designed to ensure that financial constraints do not delay critical treatment. It allows patients to undergo therapies such as CAR-T cell treatment, often used in complex and relapsed cancer cases without the burden of arranging the entire cost upfront.
“Innovation in healthcare is meaningful only when patients can access it. While tremendous progress has been made in developing advanced cellular therapies, affordability remains a significant challenge for many families” said by Amit Mookim, Chief Executive Officer, Immuneel Therapeutics.
Under this model, eligible patients can spread the treatment cost over a defined period. This is through interest-free installments, that is subject to approval. The financing process is handled independently by Arogya Finance, ensuring quick disbursal and minimal delays in treatment initiation.
This collaboration addresses one of the most pressing challenges in oncology, which is affordability. Advanced therapies are often time-sensitive, and delays in accessing funds can significantly impact outcomes.
By introducing zero-cost EMI options, the partnership ensures that patients can begin treatment immediately, improving their chances of recovery. Therefore, the Immuneel–Arogya Finance initiative represents a broader transformation in India’s healthcare ecosystem.
As more companies adopt such models, the gap between cutting-edge medical science and patient access is likely to be narrowed, bringing hope to thousands battling critical illnesses.
.jpg)
